- Home
- KRG vs PTGX Comparison
KRG vs PTGX Comparison
Compare KRG & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRG | PTGX |
|---|---|---|
| Founded | 1971 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.2B |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | KRG | PTGX |
|---|---|---|
| Price | $26.08 | $98.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $26.00 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 1.6M | 620.5K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | ★ 6750.00 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $844,365,000.00 | N/A |
| Revenue This Year | N/A | $874.25 |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | $18.96 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $20.86 | $41.29 |
| 52 Week High | $26.82 | $107.84 |
Technical Indicators
Market Signals| Indicator | KRG | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 46.91 |
| Support Level | $21.84 | $95.40 |
| Resistance Level | $26.29 | $100.00 |
| Average True Range (ATR) | 0.43 | 4.31 |
| MACD | 0.06 | -0.83 |
| Stochastic Oscillator | 64.95 | 36.81 |
Price Performance
Historical ComparisonAbout KRG Kite Realty Group Trust
Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.